找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Histiocytic Disorders; Oussama Abla,Gritta Janka Book 2018 Springer International Publishing AG 2018 langerhans cell Histiocytosis.hemopha

[復制鏈接]
樓主: fungus
41#
發(fā)表于 2025-3-28 16:36:30 | 只看該作者
Hematopoietic Cell Transplantation and Novel Therapies in Hemophagocytic Lymphohistiocytosis HLH, HCT is essential for preventing future episodes of fatal HLH in patients with genetic predisposition to HLH. Survival with HCT has increased significantly in recent years with the adoption of reduced intensity conditioning (RIC) regimens. However, RIC treatment protocols carry their own distin
42#
發(fā)表于 2025-3-28 22:25:48 | 只看該作者
43#
發(fā)表于 2025-3-29 02:09:38 | 只看該作者
Biology and Genomics of LCH and Related Disordersnslocations that produce fusion proteins which activate . occur more frequently in ECD than in LCH. The presence of some of these activating mutations in circulating cells or in CD34+ bone marrow cells suggests that these diseases may arise from transforming events in early myeloid precursors. ICH c
44#
發(fā)表于 2025-3-29 05:59:33 | 只看該作者
Central Nervous System Langerhans Cell Histiocytosisnation. Biopsies of such lesions are rare. In the few published cases biopsied, variable pathologies are described with perivascular inflammatory changes, variable neuronal loss, demyelination, and gliosis, but are nondiagnostic for CD1a+/CD207+ LCH cells. Granulomatous LCH can be responsive to chem
45#
發(fā)表于 2025-3-29 10:26:28 | 只看該作者
First-Line Treatment of Pediatric Langerhans Cell Histiocytosisactivation rates. The effect of further prolongation is being studied in the current LCH-IV protocol of the Histiocyte Society. It is to be expected that in the (near) future, the use of BRAF and MEK inhibitors may be introduced in first-line therapy, especially for very high-risk patients. For thes
46#
發(fā)表于 2025-3-29 11:43:44 | 只看該作者
47#
發(fā)表于 2025-3-29 16:01:58 | 只看該作者
48#
發(fā)表于 2025-3-29 21:34:41 | 只看該作者
49#
發(fā)表于 2025-3-30 01:58:56 | 只看該作者
50#
發(fā)表于 2025-3-30 04:02:08 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-13 16:04
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
桦南县| 阳山县| 石阡县| 苗栗县| 维西| 盱眙县| 乐陵市| 江安县| 黄平县| 遂溪县| 屏东市| 高尔夫| 休宁县| 定边县| 竹北市| 水城县| 荥经县| 游戏| 民乐县| 奎屯市| 竹北市| 临沂市| 湖北省| 东乌珠穆沁旗| 漾濞| 合川市| 四子王旗| 玛纳斯县| 平武县| 黔南| 永城市| 靖宇县| 雅江县| 隆尧县| 田阳县| 陵水| 随州市| 白朗县| 娄烦县| 岳阳县| 甘洛县|